Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer
- 27-02-2025
- Prostate Cancer
- Review
Published in:
- Authors
- Xiaolin Zhu
- Chien-Kuang C. Ding
- Rahul R. Aggarwal
- Published in
- Current Oncology Reports | Issue 4/2025
Abstract
Purpose of Review
Treatment-emergent neuroendocrine prostate cancer (NEPC) is aggressive and lethal. As androgen receptor signaling inhibitors (ARSIs) are increasingly used in earlier disease settings, treatment-emergent NEPC becomes more prevalent, and effective therapies are urgently needed. The purpose of this review was to summarize recent progress on emerging therapeutic targets of NEPC.
Recent Findings
A multitude of therapeutic targets have emerged in NEPC over recent years. These targets may represent drivers of treatment-emergent lineage plasticity or simply be overexpressed on the surface of NEPC cells. Multiple modalities have been employed to drug these targets, with promising preclinical and clinical results.
Summary
Treatment-emergent NEPC represents a distinct and clinically significant subset of castration-resistant prostate cancer (CRPC). Emerging therapeutic approaches have demonstrated encouraging efficacy and safety profiles, offering the potential to improve patient outcomes.
Advertisement
- Title
- Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer
- Authors
-
Xiaolin Zhu
Chien-Kuang C. Ding
Rahul R. Aggarwal
- Publication date
- 27-02-2025
- Publisher
- Springer US
- Keywords
-
Prostate Cancer
Prostate Cancer
Enzalutamide
SCLC
SCLC - Published in
-
Current Oncology Reports / Issue 4/2025
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269 - DOI
- https://doi.org/10.1007/s11912-025-01643-9
This content is only visible if you are logged in and have the appropriate permissions.
